What Is the Cheapest "Magnificent Seven" Stock? There are two companies investors should consider for bargain values.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Horizon Quantum Computing Pte. Lays Out Quantum Software Push at Needham Conference Horizon Quantum Computing Pte. (
NASDAQ:HQ ) used its appearance at Needham & Company’s 21st annual Technology, Media, & Consumer Conference to outline its strategy as a newly public quantum software company focused on building infrastructure for developers, hardware providers and end users.
Needham
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Nvidia Stock Is Poised to Rocket From the Booming Space Economy Nvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
With YMM Down 29%, First Beijing Bought 13 Million More Shares Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
GDS Was Already Up 47% — Pinpoint Tripled Its Stake Anyway GDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
Why Plug Power Stock Skyrocketed This Week Plug Power served up some promising news for investors this week.
Snapchat: Don't Rush to Buy This Social Media Stock Snap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
M&G Shaved 2.4% of Methanex After a Near-Doubling Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Where Could Palantir Be in 10 Years? The Bull and Bear Cases. Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.
Why Poet Technologies Stock Skyrocketed This Week Poet's new contract announcement powered huge gains for the stock.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Why Would Anyone Buy SPYM Instead of QQQ? Buying the S&P 500 instead of the Qs could help you avoid relying too heavily on tech stocks.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
